【摘要】：目的:探討米非司酮聯(lián)合血府逐瘀膠囊治療子宮肌瘤的臨床效果及安全性。方法:選擇2012年6月—2014年6月我院接診的60例子宮肌瘤患者進行研究,隨機分為觀察組和對照組。觀察組30例,采用米非司酮聯(lián)合血府逐瘀膠囊治療。對照組30例,采用米非司酮。比較兩組患者的子宮體積及子宮肌瘤的體積、激素含量(LH、FSH、P、E2)、治療效果及不良反應(yīng)(惡心,頭痛,乏力)。結(jié)果:治療后,觀察組患者與對照組患者子宮的體積相比有統(tǒng)計學(xué)差異,觀察組小于對照組(t=9.3029,P=0.0003);觀察組患者的子宮肌瘤的體積小于對照組患者,兩者相比有統(tǒng)計學(xué)差異(t=3.8804,P0.0001);觀察組患者的LH、FSH、P、E2含量均小于對照組患者,兩者相比有統(tǒng)計學(xué)差異(P0.05);觀察組的治療效果優(yōu)于對照組,兩者相比有統(tǒng)計學(xué)差異(u=2.4591,P=0.0139);不良反應(yīng)比較中,觀察組與對照組的術(shù)后頭痛發(fā)生比率為0.00%和13.33%,兩者相比有統(tǒng)計學(xué)差異(χ2=4.2857,P=0.0384);觀察組與對照組的不良反應(yīng)總的發(fā)生比率為6.67%和36.67%,兩者相比有統(tǒng)計學(xué)差異(χ2=7.9542,P=0.0048)。結(jié)論:米非司酮聯(lián)合血府逐瘀膠囊治療子宮肌瘤的臨床療效良好,安全性較高,預(yù)后良好,值得臨床推廣。
[Abstract]:Objective: to investigate the clinical effect and safety of mifepristone combined with Xuefu Zhuyu capsule in the treatment of uterine leiomyoma. Methods: from June 2012 to June 2014, 60 patients with uterine leiomyoma were randomly divided into observation group and control group. In the observation group, 30 cases were treated with mifepristone combined with Xuefu Zhuyu capsule. The control group (30 cases) was treated with mifepristone. The volume of uterus, volume of uterine leiomyoma, hormone content (LH,FSH,P,E2), therapeutic effect and adverse reactions (nausea, headache, fatigue) were compared between the two groups. Results: after treatment, there was a significant difference in the volume of uterus between the observation group and the control group, which was smaller than that in the control group (t 9.3029 Pu 0.0003). The volume of uterine leiomyoma in the observation group was smaller than that in the control group, and there was statistical difference between the two groups (t = 3.8804, P 0.0001). The content of LH,FSH,P,E2 in the observation group was lower than that in the control group (P0.05), the therapeutic effect of the observation group was better than that of the control group, and there was statistical difference between the two groups. The incidence of postoperative headache in the observation group and the control group was 0.00% and 13.33 respectively, and there was a significant difference between the two groups (蠂 ~ 2 / 4.2857 / P ~ (0.0384). The overall incidence rates of adverse reactions in the observation group and the control group were 6.67% and 36.67%, respectively. There was a significant difference between the two groups (蠂 ~ 2 = 7.9542, P < 0.0048). Conclusion: mifepristone combined with Xuefu Zhuyu capsule in the treatment of uterine leiomyoma has good clinical efficacy, high safety and good prognosis.
【作者單位】： 義烏市中心醫(yī)院婦產(chǎn)科;
【分類號】：R737.33

【參考文獻】

相關(guān)期刊論文 前10條

1 吳晚英;康佳麗;王冬昱;;35～45歲患者子宮肌瘤切除術(shù)后復(fù)發(fā)因素及手術(shù)優(yōu)選方案評估[J];廣東醫(yī)學(xué);2012年11期

2 霍翠云;李斌;;不同子宮肌瘤剔除術(shù)后復(fù)發(fā)及受孕率初步分析[J];中國婦幼保健;2011年04期

3 王瑞霞;王娜;;米非司酮藥物流產(chǎn)與繼后妊娠胚胎停育相關(guān)的探討[J];中國婦幼保健;2011年13期

4 吳若冰;程通;張雅麗;侯_z恒;溫蘭玲;;米非司酮對人耐藥卵巢癌細胞增殖、凋亡及其對紫杉醇敏感性的影響[J];中國癌癥雜志;2012年02期

5 焦俊芳;;抗生素、超短波聯(lián)合血府逐瘀膠囊治療慢性盆腔炎[J];中國實驗方劑學(xué)雜志;2011年13期

6 閆印春;;米非司酮配伍消結(jié)安膠囊治療子宮肌瘤的遠期療效觀察[J];中國現(xiàn)代醫(yī)學(xué)雜志;2011年02期

7 劉映江;劉仙明;彭松;呂發(fā)金;何敏;黃秀;張煉;陳文直;白晉;王智彪;;常規(guī)MRI在子宮肌瘤超聲消融療效評價及隨訪中的價值[J];中國醫(yī)學(xué)影像技術(shù);2011年10期

8 張輝;王玉秋;張捷;馬春燕;呂家駒;;米非司酮抑制前列腺癌PC-3細胞血管內(nèi)皮生長因子表達過程中糖皮質(zhì)激素受體的作用[J];腫瘤;2011年08期

9 劉波;馬魯波;;血府逐瘀膠囊治療血栓閉塞性脈管炎術(shù)后療效觀察[J];中國中西醫(yī)結(jié)合雜志;2012年02期

10 鄭國華;諶海英;y嚱７，

本文編號：2347530